• Company
• The erectile dysfunction tx market sales are at an all-time
• by Chon, Seung-Hyun Mar 14, 2023 05:51am

• Policy
• SGLT2 + DPP4 combi benefit expansion has increased
• by Lee, Tak-Sun Mar 14, 2023 05:50am

• Company
• Will the new prostate cancer drug Erleada be reimb in April?
• by Eo, Yun-Ho Mar 14, 2023 05:50am

• Policy
• Voluntary withdrawal of reimbursement for Tepmeko
• by Lee, Tak-Sun Mar 14, 2023 05:50am

• Policy
• Innovative plans for domestic vaccines/txs to face post-pand
• by Lee, Jeong-Hwan Mar 13, 2023 05:53am

• Company
• Eylea makes sole lead in the ₩100B nAMD Tx market
• by Jung, Sae-Im Mar 13, 2023 05:53am

• Company
• Pharmaceutical companies are fiercely competing to develop
• by Kim, Jin-Gu Mar 13, 2023 05:53am

• Company
• Gastric cancer is the first immuno-oncology option available
• by Eo, Yun-Ho Mar 13, 2023 05:53am

• Policy
• Pfizer’s Cibinqo to undergo NHIS negotiations for reimb
• by Lee, Tak-Sun Mar 13, 2023 05:53am

• Company
• GC Pharma begins develop of mRNA flu vaccine candidates
• by Hwang, Jin-joon Mar 10, 2023 05:50am